RegulatoryJun 25, 2026, 08:46 AM
IceCure Regains Nasdaq Minimum Bid Price Compliance
AI Summary
IceCure Medical Ltd. announced it has regained compliance with the Nasdaq minimum bid price requirement. The company received written notice from Nasdaq on June 18, 2026, confirming it met the Nasdaq Listing Rule 5550(a)(2) by maintaining a closing bid price of $1.00 or greater for 10 consecutive business days from June 4 to June 17, 2026. As a result, Nasdaq considers the bid price deficiency matter closed.
Key Highlights
- IceCure Medical regained compliance with Nasdaq Listing Rule 5550(a)(2).
- The rule requires a minimum bid price of $1.00 per share.
- Compliance was achieved by maintaining a closing bid price of $1.00 or greater.
- The minimum bid price was maintained for 10 consecutive business days.
- The compliance period was from June 4 to June 17, 2026.
- Nasdaq now considers the bid price deficiency matter closed.
Price Impact
More from ICCM